Press Releases May 8, 2026 07:00 AM

MapLight Therapeutics to Participate in Upcoming Investor Conferences

MapLight Therapeutics to Present at Key 2026 Healthcare Investor Conferences

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
MPLT

MapLight Therapeutics, a clinical-stage biopharmaceutical company specializing in central nervous system disorders, announced its management team's participation in the 2026 RBCCM Global Healthcare Conference and the 2026 Jefferies Global Healthcare Conference. The company focuses on developing circuit-specific pharmacotherapies using a novel discovery platform targeting neural circuits linked to diseases.

MapLight Therapeutics to Participate in Upcoming Investor Conferences
MPLT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • MapLight Therapeutics will present and host one-on-one meetings at two major 2026 healthcare investor conferences in New York.
  • The company is developing novel pharmacotherapies aimed at central nervous system disorders by targeting specific neural circuits.
  • Webcasts and recordings of the presentations will be made available on MapLight Therapeutics' investor relations website.

SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences:

Event: 2026 RBCCM Global Healthcare Conference (New York, NY)
Date: Tuesday, May 19th
Format: Presenting and hosting 1x1 meetings

Event: 2026 Jefferies Global Healthcare Conference (New York, NY)
Date: Wednesday, June 3rd
Format: Presenting and hosting 1x1 meetings

Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.

For investor inquiries: [email protected]

For media inquiries: [email protected]


Risks

  • As a clinical-stage biopharmaceutical company, MapLight faces typical risks including clinical trial outcomes and regulatory approval uncertainties.
  • The success of the company's therapeutic platform depends on the validation of its novel approach to circuit-specific targeting in central nervous system disorders.
  • Market reception may be impacted by the company's pipeline progress and competitive landscape within the CNS therapeutic sector.

More from Press Releases

Space Exploration Technologies Corporation to Join the Nasdaq-100 Index® Beginning July 7, 2026 Jun 26, 2026 XMax Announces Up to Approximately US$25 million in AI API-Related Service Contracts and Expansion into GPU-as-a-Service Jun 26, 2026 Cartesian Growth Corporation IV Announces Closing of $275 Million Initial Public Offering Jun 26, 2026 dLocal added to membership of US small-cap Russell 2000® Index Jun 26, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Jun 26, 2026